FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048388428> ?p ?o ?g. }

• W3048388428 abstract "Background While there have been encouraging preliminary clinical results for immune checkpoint inhibitors (ICIs) in BTCs, it remains a challenge to identify the subset of patients who may benefit. In this study, we evaluated the efficacy of ICI treatment in patients with advanced BTCs, and explored potential biomarkers that are predictive of response. Methods The study enrolled 26 patients with advanced microsatellite stable BTCs (15 with gallbladder cancers [GCs] and 11 with intrahepatic cholangiocarcinoma [ICCs]) who received ICI treatment. Targeted next-generation sequencing (NGS) was performed on tumor tissue samples collected from 17 patients. Clinical and genomic characteristics were assessed for the correlation with clinical outcome. Results Analysis of the baseline clinical characteristics showed that performance score (PS) of 0 was associated with a better prognosis than PS of 1 (HR = 1.08 × 109; 95% CI, 0∼Inf; P = .002). No significant correlations were found between clinical outcome and inflammation-related indicators. NGS profiling of the available tumor tissues, revealed largely non-overlapping somatic alterations between GCs and ICCs. Mutations in LRP1B (HR = 0.26; 95% CI, 0.06-1.21; P = .067), ERBB2 (HR = 0.15; 95% CI, 0.02-1.19; P = .04), or PKHD1 (HR < 0.01; 95% CI, 0-Inf; P = .04) showed strong association with increased progression-free survival (PFS) benefit. Subsequent analysis showed that alterations in the RTK-RAS pathway were associated with improved outcomes (HR = 0.12; 95% CI, 0.02-0.63; P = .003). Tumor mutation burden (TMB) was higher in patients with GC than those with ICC, and was associated with LRP1B mutations (P = .032). We found that patients with 19q amplification (19q Amp) and 9p deletion (9p Del) had poor PFS outcome (19q Amp, HR = 15.4; 95% CI, 2.7-88.5; P < .001; 9p Del; HR = 4.88 × 109; 95% CI, 0-Inf; P < .001), while those with chromosomal instability derived PFS benefit (HR = 0.24; 95% CI, 0.05-1.17; P = .057). Conclusion Our study identified several potential clinical and genomic features that may serve as biomarkers of clinical response to ICIs in advanced BTCs patients. A larger sample size is required for further verification." @default.
• W3048388428 created "2020-08-18" @default.
• W3048388428 creator A5003742311 @default.
• W3048388428 creator A5004901295 @default.
• W3048388428 creator A5007677720 @default.
• W3048388428 creator A5010738468 @default.
• W3048388428 creator A5011916630 @default.
• W3048388428 creator A5012288680 @default.
• W3048388428 creator A5016567204 @default.
• W3048388428 creator A5016585111 @default.
• W3048388428 creator A5017947601 @default.
• W3048388428 creator A5032349293 @default.
• W3048388428 creator A5042170464 @default.
• W3048388428 creator A5044012938 @default.
• W3048388428 creator A5046804024 @default.
• W3048388428 creator A5048541371 @default.
• W3048388428 creator A5049709428 @default.
• W3048388428 creator A5055812068 @default.
• W3048388428 creator A5062369400 @default.
• W3048388428 creator A5063909638 @default.
• W3048388428 creator A5064805356 @default.
• W3048388428 creator A5077965583 @default.
• W3048388428 creator A5091501300 @default.
• W3048388428 creator A5091758507 @default.
• W3048388428 date "2020-08-01" @default.
• W3048388428 modified "2023-10-12" @default.
• W3048388428 title "Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response" @default.
• W3048388428 cites W109558269 @default.
• W3048388428 cites W1903979702 @default.
• W3048388428 cites W1982488143 @default.
• W3048388428 cites W2021775623 @default.
• W3048388428 cites W2080809959 @default.
• W3048388428 cites W2097995306 @default.
• W3048388428 cites W2107211326 @default.
• W3048388428 cites W2115261608 @default.
• W3048388428 cites W2131271579 @default.
• W3048388428 cites W2155943701 @default.
• W3048388428 cites W2213687129 @default.
• W3048388428 cites W2321683347 @default.
• W3048388428 cites W2337387091 @default.
• W3048388428 cites W2405513305 @default.
• W3048388428 cites W2560367415 @default.
• W3048388428 cites W2572174216 @default.
• W3048388428 cites W2574604975 @default.
• W3048388428 cites W2600590996 @default.
• W3048388428 cites W2739132742 @default.
• W3048388428 cites W2770612611 @default.
• W3048388428 cites W2790922923 @default.
• W3048388428 cites W2794662918 @default.
• W3048388428 cites W2796207838 @default.
• W3048388428 cites W2799610897 @default.
• W3048388428 cites W2805926640 @default.
• W3048388428 cites W2883867140 @default.
• W3048388428 cites W2889646458 @default.
• W3048388428 cites W2894518105 @default.
• W3048388428 cites W2904444972 @default.
• W3048388428 cites W2920331770 @default.
• W3048388428 cites W2921913890 @default.
• W3048388428 cites W2945998739 @default.
• W3048388428 cites W2946053006 @default.
• W3048388428 cites W2946272661 @default.
• W3048388428 cites W2947713225 @default.
• W3048388428 cites W2947823476 @default.
• W3048388428 cites W2968115401 @default.
• W3048388428 cites W2970868115 @default.
• W3048388428 cites W2991083833 @default.
• W3048388428 cites W2993453764 @default.
• W3048388428 cites W3030632902 @default.
• W3048388428 cites W4255602289 @default.
• W3048388428 doi "https://doi.org/10.1002/ctm2.118" @default.
• W3048388428 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7423188" @default.
• W3048388428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32898339" @default.
• W3048388428 hasPublicationYear "2020" @default.
• W3048388428 type Work @default.
• W3048388428 sameAs 3048388428 @default.
• W3048388428 citedByCount "13" @default.
• W3048388428 countsByYear W30483884282021 @default.
• W3048388428 countsByYear W30483884282022 @default.
• W3048388428 countsByYear W30483884282023 @default.
• W3048388428 crossrefType "journal-article" @default.
• W3048388428 hasAuthorship W3048388428A5003742311 @default.
• W3048388428 hasAuthorship W3048388428A5004901295 @default.
• W3048388428 hasAuthorship W3048388428A5007677720 @default.
• W3048388428 hasAuthorship W3048388428A5010738468 @default.
• W3048388428 hasAuthorship W3048388428A5011916630 @default.
• W3048388428 hasAuthorship W3048388428A5012288680 @default.
• W3048388428 hasAuthorship W3048388428A5016567204 @default.
• W3048388428 hasAuthorship W3048388428A5016585111 @default.
• W3048388428 hasAuthorship W3048388428A5017947601 @default.
• W3048388428 hasAuthorship W3048388428A5032349293 @default.
• W3048388428 hasAuthorship W3048388428A5042170464 @default.
• W3048388428 hasAuthorship W3048388428A5044012938 @default.
• W3048388428 hasAuthorship W3048388428A5046804024 @default.
• W3048388428 hasAuthorship W3048388428A5048541371 @default.
• W3048388428 hasAuthorship W3048388428A5049709428 @default.
• W3048388428 hasAuthorship W3048388428A5055812068 @default.
• W3048388428 hasAuthorship W3048388428A5062369400 @default.
• W3048388428 hasAuthorship W3048388428A5063909638 @default.
• W3048388428 hasAuthorship W3048388428A5064805356 @default.
• W3048388428 hasAuthorship W3048388428A5077965583 @default.

• next